TY - JOUR T1 - High mortality in COPD patients with isolation of <em>aspergillus spp</em> in bronchial secretions JF - European Respiratory Journal JO - Eur Respir J VL - 42 IS - Suppl 57 SP - P2064 AU - Roberto Chalela Rengifo AU - Pilar Ausin Herrero AU - Antonio Ferrer Monreal AU - Juan Pablo Horcajada AU - Susana Font AU - Juan Gomez AU - Joaquin Gea Guiral Y1 - 2013/09/01 UR - http://erj.ersjournals.com/content/42/Suppl_57/P2064.abstract N2 - Introduction: COPD is a risk factor for pulmonary aspergillosis (PA). Antifungal treatment in COPD patients and respiratory isolation of Aspergillus spp without radiographic findings remains controversial.Objective: to describe the clinical and functional characteristics of COPD patients with exacerbation and isolation of Aspergillus spp in bronchial secretions, and to compare the differences between invasive and non-invasive cases.Methods: we selected patients with Aspergillus spp in bronchial secretions for 6 years. Patients with aspergilloma, allergic bronchopulmonary aspergillosis, cancer or severe immunosuppression were excluded. Patients were classified according to main respiratory diagnoses. We collected data on clinical features, treatment and mortality for two years. The EORTC/MSG criteria for diagnosis of invasive aspergillosis was used.Results: 98 patients with 199 positive cultures were studied: COPD (69), asthma (10), post-tuberculosis sequelae (8), bronchiectasis (5), and other (6).View this table:ResultsConclusions: COPD patients with PA have a high mortality rate per year regardless of whether they present invasive disease or not; only 1/3 patients with non-invasive aspergillosis received antifungal treatment. Early detection and anti-fungal treatment could be effective to improve survival in these patients. Coinfection with P. aeruginosa is frequently seen (almost 2/3) in non-invasive disease cases. ER -